Methylphenidate Clause Samples

The 'Methylphenidate' clause defines the terms and conditions under which methylphenidate, a prescription medication commonly used to treat attention deficit hyperactivity disorder (ADHD), may be prescribed, dispensed, or administered. This clause typically outlines the requirements for medical evaluation, documentation, and compliance with relevant laws and regulations regarding controlled substances. By establishing clear guidelines for the use of methylphenidate, the clause helps ensure patient safety, legal compliance, and proper management of the medication within the scope of the agreement.
Methylphenidate. Plain – Ritalin® and Medikinet®: Child 4-5 years old (unlicensed), initially 2.5 mg twice daily, increased in steps of 2.5 mg daily if required, at weekly intervals For Children over 6 years initially 5mg once or twice daily with or after breakfast and lunch, increasing if necessary in weekly intervals of 5-10mg in 2 to 3 divided doses. The maximum licensed dose for methylphenidate is 60mg daily, with 90mg daily used in some specialist centres, which is supported by NICE (NICE NG 87 March 2018). In some children rebound hyperactivity may occur if the effect of the drug wears off in the evening. An additional dose later in the day may eliminate this difficulty but may disturb sleep. Equasym XL®: Child 6* years or over, initially 10mg once daily (in the morning before breakfast), increasing if necessary in weekly intervals to a maximum of 60mg daily. For children 4-5 years 10mg daily (in the morning with breakfast) could be considered but this is unlicensed. Medikinet XL®: Child 6* years or over, initially 10mg once daily (in the morning with breakfast), adjusted according to response at weekly intervals to a maximum of 60mg daily. For children 4-5 years old Medikinet XL 5mg once daily (in the morning before breakfast) could be considered, with this being unlicensed Concerta XL®, Xaggitin XL Matoride XL® & Xenidate XL®: Child 6* years or over initially 18mg once daily (in the morning), increasing if necessary in weekly increments of 18mg up to a maximum licensed dose of 54mg once daily. For children 4-5 years 18mg daily (in the morning with breakfast) could be considered but this is unlicensed. A 15mg dose of all other formulations of methylphenidate is considered equivalent to Concerta XL® 18mg and branded generic versions of this. The unlicensed dose of Concerta XL® 72mg is therefore equivalent to the licensed maximum 60mg dose of Ritalin®, Medikinet®, Equasym XL® or Medikinet XL®. The usual starting dosage for children aged 3-5 years is 2.5mg a day, increased if necessary by 2.5mg a day at weekly intervals; for children aged 6 years and over, the usual starting dose is 2.5mg 2 to 3 times per day increasing if necessary by 5mg per day at weekly intervals. The usual upper limit is 20mg a day though some older children have needed 40mg or more for optimal response. Maintenance dose should be given in 2 to 4 divided doses. Lisdexamfetamine is a pro-drug formulation of dexamfetamine, which is converted to free dexamfetamine by enzymes present on red blood cell...
View SourceView Similar (3)
Methylphenidate. Plain – Ritalin® and Medikinet®: Child over 6 years initially 5mg once or twice daily e.g. with or after breakfast and lunch, increasing if necessary in weekly intervals of 5-10mg in 2 to 3 divided doses. The maximum licensed dose for methylphenidate is 60mg daily, with 90mg daily used in some specialist centres, which is supported by NICE (NICE CG 72 September 2008). In some children rebound hyperactivity may occur if the effect of the drug wears off in the evening. An additional dose later in the day may eliminate this difficulty but may disturb sleep.
View Source
Methylphenidate. Diagnosis or history of severe depression, anorexia nervosa or anorexic disorders, suicidal tendencies, psychotic symptoms, mania, schizophrenia, severe mood disorders, or psychopathic or borderline personality disorder, vasculitis or stroke. Lisdexamfetamine▼ - Advanced arteriosclerosis, agitated states, hyperexcitability, hyperthyroidism, moderate hypertension, severe hypertension, symptomatic cardiovascular disease. Dexamfetamine - History of drug abuse or alcohol abuse - Pregnancy and lactation. Atomoxetine Not be used in combination with monoamine oxidase inhibitors (MAOIs), narrow angle glaucoma, pheochromocytoma, severe cardiovascular and cerebrovascular disorders. Monitoring Requirements: o Blood pressure & pulse every 6 months o Height and weight every 6 months and plotted on a growth chart o If the patient has a change in height or weight that crosses two percentile lines, then this suggests an aberrant growth trajectory and should be reffered to the specialist. o If growth is significantly affected by drug treatment (that is, the child or young person has not met the height expected for their age), the option of a planned break in treatment over school holidays should be considered to allow 'catch-up' growth to occur o Strategies to manage decreased weight gain in children, include: o taking medication either with or after food, rather than before meals o taking additional meals or snacks early in the morning or late in the evening when the stimulant effects of the drug have worn off o obtaining dietary advice o consuming high-calorie foods of good nutritional value o No routine measurement of LFTs / FBC, but measure if signs of liver impairment (seen with atomoxetine) o In line with other shared care documents, see ‘areas of responsibility’
View Source
Methylphenidate. Generic prescribing of MR Methylphenidate is not recommended due to cost implications and impact of monitoring of patient response to treatment as a result of increased variability in different brands being supplied to the young person. There is also the added factor that modified release preparations have varying release profiles and generic prescribing can lead to the supply of an inappropriate MR formulation product which does not treat meet the clinical needs of the young person. However, where the clinician (CAMHS/ Paediatricians) has assessed a young person would benefit from a modified release profile, the following is recommended: • To prescribe by brands and not generically as different versions of modified-release preparations may not have the same clinical effect • To prescribe a cheaper bio-equivalent brand as agreed between ELFT, CAMHS, Paediatricians and the CCGs • Any switch in bioequivalent MR Methylphenidate brand must be agreed with the clinician (CAMHS/ Paediatricians), GP, parent/ carer and where appropriate, the young person. • Written medication information must be provided on the brand where a bioequivalent switch has been agreed Where the young person is under the care of the Paediatrician and/ or CAMHS team, the GP can seek advice from the relevant specialist with regards to making any changes and/ or discontinuation of medication Adverse effect1 Symptoms/ signs Occurs with MPH, ATMX, DEX, LDE or GUA? Frequency* Suggested actions Gastro-intestinal symptoms Stomach ache MPH, LDEX, GUA Very common Usually transient may occur on starting treatment but these go after a few days. Possibly helped by taking the medication after food. Decreased appetite/ anorexia MPH, DEX, ATMX Common Usually transient. Take medication with food rather than before meals. For MPH, DEX: additional meals or snacks taking early in the morning or in the late evening when the 1 For a full list of adverse effects, please consult the most recent version of the BNFC, or the manufacturers Summary of Product Characteristics (SPC). stimulant effects of the drugs have worn off may help. Dry mouth MPH, DEX, LDEX, GUA Common Usually transient. Encourage fluid intake, chewing of sugar-free gum or sucking sugar-free boiled sweets. Abdominal pain, nausea and vomiting MPH, DEX, ATMX, GUA Common Usually at beginning of treatment & may be helped by taking with food. Constipation ATMX, GUA Common Maintain a good fluid intake, a fibrous diet and exercise regularly Psychiatric di...
View Source

Related to Methylphenidate

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • Therapies Acupuncture and acupuncturist services, including x-ray and laboratory services. • Biofeedback, biofeedback training, and biofeedback by any other modality for any condition. • Recreational therapy services and programs, including wilderness programs. • Services provided in any covered program that are recreational therapy services, including wilderness programs, educational services, complimentary services, non- medical self-care, self-help programs, or non-clinical services. Examples include, but are not limited to, Tai Chi, yoga, personal training, meditation. • Computer/internet/social media based services and/or programs. • Recreational therapy. • Aqua therapy unless provided by a physical therapist. • Maintenance therapy services unless it is a habilitative service that helps a person keep, learn or improve skills and functioning for daily living. • Aromatherapy. • Hippotherapy. • Massage therapy rendered by a massage therapist. • Therapies, procedures, and services for the purpose of relieving stress. • Physical, occupational, speech, or respiratory therapy provided in your home, unless through a home care program. • Pelvic floor electrical and magnetic stimulation, and pelvic floor exercises. • Educational classes and services for speech impairments that are self-correcting. • Speech therapy services related to food aversion or texture disorders. • Exercise therapy. • Naturopathic, homeopathic, and Christian Science services, regardless of who orders or provides the services. • Eye exercises and visual training services. • Lenses and/or frames and contact lenses for members aged nineteen (19) and older. • Vision hardware purchased from a non-network provider. • Non-collection vision hardware. • Lenses and/or frames and contact lenses unless specifically listed as a covered healthcare service.

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Product NYISO will provide Energy Resource Interconnection Service and Capacity Resource Interconnection Service to Developer at the Point of Interconnection.